Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04480840




Registration number
NCT04480840
Ethics application status
Date submitted
13/07/2020
Date registered
21/07/2020
Date last updated
12/04/2024

Titles & IDs
Public title
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
Scientific title
A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)
Secondary ID [1] 0 0
INTEGRIS-PSC
Secondary ID [2] 0 0
PLN-74809-PSC-203
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary Sclerosing Cholangitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PLN-74809
Treatment: Drugs - Placebo

Placebo Comparator: Placebo -

Experimental: PLN-74809 Dose Level 1 - Dose: 40 mg;

Experimental: PLN-74809 Dose Level 2 - Dose: 80 mg; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1

Experimental: PLN-74809 Dose Level 3 - Dose: 160 mg; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 2

Experimental: PLN-74809 Dose Level 4 - Dose: 320 mg; PLN-74809 Dose Level 4 following PLN-74809 Dose Level 3


Treatment: Drugs: PLN-74809
PLN-74809

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with treatment-related adverse events and laboratory abnormalities, as assessed by CTCAE v5.0
Timepoint [1] 0 0
12-48 weeks
Secondary outcome [1] 0 0
Assessment of PLN-74809 plasma concentrations
Timepoint [1] 0 0
12-48 weeks

Eligibility
Key inclusion criteria
- Established clinical diagnosis of large duct PSC based on an abnormal cholangiography
as assessed by magnetic resonance cholangiopancreatography (MRCP), endoscopic
retrograde cholangiopancreatography (ERCP), and/or percutaneous transhepatic
cholangiopancreatography (PTC) in the context of cholestatic liver chemistry

- Suspected liver fibrosis, as defined by liver stiffness measurement (LSM), assessed by
ultrasound-based transient elastography (TE, FibroScan®) OR Enhanced Liver Fibrosis
(ELF) Score OR Historical liver biopsy showing fibrosis without cirrhosis (by any
scoring system) OR Magnetic resonance elastography (MRE)

- Serum ALP concentration within normal limits or > 1 times the upper limit of normal
(ULN)

- Participants receiving treatment for IBD are allowed, if on a stable dose from
screening and expected to remain stable for the duration of the study

- Serum AST and ALT concentration = 5 times the upper limit of normal

- If receiving treatment with UDCA, therapy is at a dose of < 25 mg/kg/day, has been
stable for at least 3 months before screening.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Other causes of liver disease, including secondary sclerosing cholangitis or viral,
metabolic, or alcoholic liver disease, as assessed clinically

- Known or suspected overlapping clinical and histologic diagnosis of autoimmune
hepatitis

- Small duct PSC with no evidence of large duct involvement (evidence of PSC on
historical liver histology, with normal bile ducts on cholangiography)

- Presence of liver cirrhosis as assessed by liver histology, ultrasound-based liver
stiffness measurement, ELF score, MRE, and/or signs and symptoms of hepatic
decompensation (including but not limited to, jaundice, ascites, variceal hemorrhage,
and/or hepatic encephalopathy.

- Serum ALP concentration > 10 times the upper limit of normal.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/07/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/03/2024
Sample size
Target
Accrual to date
Final
121
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Liverpool Hospital: Department of Gastroenterology and Hepatology - Liverpool
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [5] 0 0
The Alfred - Melbourne
Recruitment hospital [6] 0 0
St. Vincent's Hospital - Melbourne
Recruitment hospital [7] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
3004 - Melbourne
Recruitment postcode(s) [6] 0 0
3065 - Melbourne
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
Tennessee
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Virginia
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Austria
State/province [15] 0 0
Graz
Country [16] 0 0
Austria
State/province [16] 0 0
Vienna
Country [17] 0 0
Belgium
State/province [17] 0 0
Bruxelles
Country [18] 0 0
Belgium
State/province [18] 0 0
Edegem
Country [19] 0 0
Belgium
State/province [19] 0 0
Gent
Country [20] 0 0
Belgium
State/province [20] 0 0
Leuven
Country [21] 0 0
Canada
State/province [21] 0 0
Alberta
Country [22] 0 0
Canada
State/province [22] 0 0
British Columbia
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
France
State/province [25] 0 0
Grenoble
Country [26] 0 0
France
State/province [26] 0 0
Lille
Country [27] 0 0
France
State/province [27] 0 0
Paris
Country [28] 0 0
France
State/province [28] 0 0
Strasbourg
Country [29] 0 0
France
State/province [29] 0 0
Villejuif
Country [30] 0 0
Germany
State/province [30] 0 0
Berlin
Country [31] 0 0
Germany
State/province [31] 0 0
Erlangen
Country [32] 0 0
Germany
State/province [32] 0 0
Hamburg
Country [33] 0 0
Germany
State/province [33] 0 0
Heidelberg
Country [34] 0 0
Germany
State/province [34] 0 0
Mainz
Country [35] 0 0
Netherlands
State/province [35] 0 0
Amsterdam
Country [36] 0 0
Netherlands
State/province [36] 0 0
Leiden
Country [37] 0 0
Netherlands
State/province [37] 0 0
Rotterdam
Country [38] 0 0
United Kingdom
State/province [38] 0 0
Norfolk
Country [39] 0 0
United Kingdom
State/province [39] 0 0
Oxford
Country [40] 0 0
United Kingdom
State/province [40] 0 0
Birmingham
Country [41] 0 0
United Kingdom
State/province [41] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pliant Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to
evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary
sclerosing cholangitis and suspected liver fibrosis
Trial website
https://clinicaltrials.gov/ct2/show/NCT04480840
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pliant Therapeutics Medical Monitor
Address 0 0
Pliant Therapeutics, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04480840